Our data revealed IGF2BP1 at differential levels among intrinsic subtypes of breast cancer (Normal, n = 40; LumA, n = 562; LumB, n = 204; Basal, n = 195; Her2, n = 82: Kruskal–Wallis test, p < 0.001), which raised the question whether IGF2BP1 was related to breast cancer prognosis. This evidence concerns the gene IGF2BP1 and breast carcinoma.